

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS:

1.-21. (Cancelled)

22. (Currently Amended) The method according to ~~claim 19~~ claim 55, wherein said vaccinia virus is the ~~modified vaccinia virus such as~~ native Modified Vaccinia virus Ankara (MVA) or a recombinant ~~vaccinia virus~~ thereof.

23.-24. (Cancelled)

25. (Currently Amended) The method according to ~~claim 24~~ claim 55, wherein said the avian embryonic derived stem cells ~~obtained~~ produced in step [[c)]] 1) are capable of proliferating for at least 600 days.

26.-29. (Cancelled)

30. (Currently Amended) The method according to ~~claim 24~~ claim 55, wherein said the avian embryonic derived cell lines produced in step 1) are non-adherent stem cells which proliferate in suspension in a medium free of exogenous growth factors.

31. (Currently Amended) The method according to ~~claim 24~~ claim 55, wherein ~~said~~ the avian embryonic derived cell lines produced in step 1) are non-adherent stem cells which proliferate in suspension in a medium free of serum (serum-free medium).

32. (Currently Amended) The method according to ~~claim 19~~ claim 55, wherein ~~said~~ the avian embryonic derived cell lines produced in step 1) are non-adherent stem cells which proliferate in suspension in a medium free of exogenous growth factors and serum.

33. (Currently Amended) The method according ~~claim 19~~ claim 55, wherein ~~said~~ the avian embryonic derived cell lines produced in step 1) have at least one of the following characteristics:

- a high nucleo-cytoplasmic ratio,
- an endogenous alkaline phosphatase activity,
- an endogenous telomerase activity,
- a reactivity with specific antibodies selected from the group of antibodies consisting of SSEA-1 (TEC01), SSEA-3 and EMA-1.

34. (Cancelled)

35. (Currently Amended) The method according to ~~claim 34~~ claim 55, wherein said basal medium is selected from the group consisting of DMEM, GMEM, HamF12 and McCoy basal medium supplemented with additives.

36.-54. (Cancelled)

55. (New) A method for replicating a native or recombinant vaccinia virus comprising the steps of:

- 1) producing avian embryonic derived stem cells by:
 - a) culturing avian embryonic cells in a complete culture medium complemented in serum containing:
 - i) exogenous growth factors comprising the trophic factors SCF, IGF-1 and bFGF, and cytokines whose action is through a receptor which is associated with the gp130 protein, said cytokines being selected from the group consisting of LIF, interleukin 11, interleukin 6, interleukin 6 receptor, CNFT, oncostatin and cardiotrophin; and
 - ii) a feeder layer;
 - b) passage by modifying the culture medium so as to obtain the withdrawal of said growth factors, of the serum and/or of the feeder layer;
 - c) establishing adherent or non-adherent cell lines capable of proliferating in a basal medium in the absence of exogenous growth factors, serum and/or inactivated feeder layer;
- 2) inoculating the resultant avian embryonic derived stem cells with viral particles of said vaccinia virus; and
- 3) culturing said cells in a basal medium until cell lysis occurs and newly produced viral particles of said vaccinia virus are released in said medium.

56. (New) The method according to claim 55, wherein said avian embryonic cells are chicken or duck embryonic cells.

57. (New) The method according to claim 55, wherein the feeder layer is inactivated.

58. (New) The method according to claim 55, wherein the avian embryonic derived stem cells produced in step 1) are non-adherent stem cells which proliferate in suspension in a medium free of exogenous growth factors, serum and feeder cells.